Intensive Insulin Therapy With Tight Glycemic Control to Improve Outcomes After Endovascular Therapy for Acute Ischemic Stroke

Completed · Phase 1

Conditions studied: Ischemic Stroke

In brief

The purpose of this study is to determine the safety and efficacy of lowering glucose (blood sugar), in addition to endovascular therapy, after acute ischemic stroke. The study will determine if lowering glucose (blood sugar) in addition to endovascular therapy will improve 90-day functional and neurological outcomes in comparison to standard glycemic care in patients with acute ischemic stroke. The study will involve treatment of 100 (50 intensive insulin therapy and 50 standard glycemic control) non-diabetic patients presenting within 8 hours of acute ischemic stroke who have undergone endovascular therapy.

Key facts

Study ID

NCT02054429

Run by

University at Buffalo

People needed

30

Starts

2013-01-01

Expected to finish

2016-12-31

Last updated by the study team

2025-08-08

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-85 years
• All patients attending the emergency department (ED) of Kaleida health within 24 hrs of symptoms onset suggestive of an anterior circulation ischemic stroke.
• CT perfusion suggesting Ischemic Core less than 30% of Penumbra territory.
• No history of diabetes
• First neurological event
• Clinical signs consistent with the diagnosis of ischemic stroke, including impairment of language, motor function, cognition and/or gaze, vision, or neglect. Ischemic stroke is defined as an event characterized by the sudden onset of a focal neurologic deficit presumed to be due to cerebral ischemia after exclusion of ICH with a baseline CT
• The signal stroke should be (a) acute, (b) the most recent significant, acute worsening of serial neurologic events, or (c) related to a diagnostic radiographic procedure but not an interventional procedure
• Minimum NIHSS score >4, except for isolated aphasia or isolated hemianopsia
• Angiographic evidence of a clot in the anterior intracranial or extracranial circulation consistent with the neurologic deficit with complete occlusion (TICI grade 0) or contrast penetration with minimal perfusion (TICI grade 1).
• Signed informed consent to participate given by patient or legal representative.

You may not qualify if…

• Coma
• Neurologic signs that are rapidly improving by the time of randomization or treatment- a 4-point improvement from baseline NIHSS , or increase to absolute NIHSS > 30 before randomization or treatment
• Major stroke symptoms- NIHSS >30
• Seizure at the onset of stroke
• Stroke due to a neurointerventional procedure for treatment of a cerebral aneurysm and/or cerebral arteriovenous malformation (stroke due to diagnostic cerebral angiography or cardiac catheterization might be treated)
• Clinical presentation suggestive of subarachnoid hemorrhage, even when the initial CT scan is normal.
• Previous known ICH at any time, neoplasm, and/or subarachnoid hemorrhage.
• Patients with a known arteriovenous malformation or aneurysm, with or without any evidence of associated hemorrhage.
• Presumed septic embolus
• Known hereditary or acquired hemorrhagic diathesis, eg, aPTT or prothrombin time greater than normal; unsupported coagulation factor deficiency.
• Baseline laboratory values that reveal platelets are <30 000/µL, hematocrit or platelet cell volume <25 volume %, or international normalized ratio >1.7. (Any patient receiving heparin at the onset of stroke symptoms must have an aPTT 2 times the upper limit of normal before randomization. Patients receiving low-molecular-weight heparin might need to be excluded because an anticoagulant effect is not measured by aPTT.)
• Pregnancy, lactation, or parturition within the previous 30 days.
• Known serious sensitivity to radiographic contrast agents.
• Other serious, advanced, or terminal illness such that life expectancy is <1 year.
• Current participation in another research treatment protocol.
• Previous participation in an acute stroke study.
• Any condition in which angiography is contraindicated.
• Uncompensated hypertension at study entry or hypertension requiring aggressive treatment to reduce blood pressure to non-hypertensive limits. Uncompensated hypertension is defined as systolic blood pressure >180 mm Hg or diastolic blood pressure 100 mm Hg on 3 repeated measures at least 10 minutes apart. Aggressive treatment is defined as the need for a continuous, parenteral antihypertensive, such as a nitroprusside drip, or the need to administer >3 doses of a parenteral antihypertensive, such as labetalol, hydralazine, nicardepine.
• Dependency on renal dialysis or known serum creatinine > 2.0mg/dl
• Serum glucose at admission <80mg/dl
• All known diabetic patients
• Random Admission glucose > 200mg/dl
• High-attenuation lesion on CT consistent with a hemorrhage of any degree in any location.
• Evidence of a significant mass effect with a midline shift due to a large infarct
• Acute hypodense parenchymal lesion on CT or effacement of the cerebral sulci in more than one third of the MCA territory or suspected stroke region

Where it is running

• University of Buffalo Neurosurgery — Buffalo, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.